{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-168554","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2024-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.675565+00:00","generated_at":"2026-06-01T01:38:31.116563+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vir Biotech gets FDA IND clearance & Fast Track for hepatitis delta combo therapy","bullets":["FDA cleared IND and granted Fast Track for tobevibart + elebsiran for chronic hepatitis delta.","Phase 2 SOLSTICE 24-week data expected Q4 2024; preliminary data showed high virologic response.","Company plans ECLIPSE trial to support potential registration, comparing combo to standard of care.","CEO Marianne De Backer says IND clearance underscores potential to transform treatment landscape.","Hepatitis delta affects at least 12 million people globally; considered most severe viral hepatitis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-168554","json":"https://secwatch.observer/filing/0001193125-24-168554.json","markdown":"https://secwatch.observer/filing/0001193125-24-168554.md","text":"https://secwatch.observer/filing/0001193125-24-168554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000119312524168554/0001193125-24-168554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000119312524168554/d835539d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:38:31.116563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001178913-26-002988","ticker":"SLXN","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-29T11:00:25+00:00","headline":"Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted","event_type":"regulatory","sec_items":["3.03","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002988","json":"https://secwatch.observer/filing/0001178913-26-002988.json","markdown":"https://secwatch.observer/filing/0001178913-26-002988.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/0001178913-26-002988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002988/zk2635442.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-062172","ticker":"RR","company_name":"RICHTECH ROBOTICS INC.","filed_at":"2026-05-28T20:49:32+00:00","headline":"Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062172","json":"https://secwatch.observer/filing/0001213900-26-062172.json","markdown":"https://secwatch.observer/filing/0001213900-26-062172.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/0001213900-26-062172-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1963685/000121390026062172/ea0292546-8k_richtech.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-240645","ticker":"JAGX","company_name":"Jaguar Health, Inc.","filed_at":"2026-05-27T13:10:06+00:00","headline":"Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-240645","json":"https://secwatch.observer/filing/0001193125-26-240645.json","markdown":"https://secwatch.observer/filing/0001193125-26-240645.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/0001193125-26-240645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/d129501d8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-025171","ticker":"MBOT","company_name":"Microbot Medical Inc.","filed_at":"2026-05-26T12:30:22+00:00","headline":"Microbot Medical receives Israeli regulatory approval for LIBERTY System, first outside U.S.","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025171","json":"https://secwatch.observer/filing/0001493152-26-025171.json","markdown":"https://secwatch.observer/filing/0001493152-26-025171.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/883975/000149315226025171/0001493152-26-025171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/883975/000149315226025171/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-060667","ticker":"LRHC","company_name":"La Rosa Holdings Corp.","filed_at":"2026-05-22T21:20:15+00:00","headline":"La Rosa Holdings receives Nasdaq deficiency notice for late 10-K and 10-Q filings","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060667","json":"https://secwatch.observer/filing/0001213900-26-060667.json","markdown":"https://secwatch.observer/filing/0001213900-26-060667.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1879403/000121390026060667/0001213900-26-060667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1879403/000121390026060667/ea0291964-8k_larosa.htm"},"side_by_side_evidence":null},{"accession":"0001731122-26-000781","ticker":"AVXL","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2026-05-22T12:15:26+00:00","headline":"Anavex receives Nasdaq delinquency notice for late 10-Q filing; deadline July 20, 2026","event_type":"regulatory","sec_items":["3.01","8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000781","json":"https://secwatch.observer/filing/0001731122-26-000781.json","markdown":"https://secwatch.observer/filing/0001731122-26-000781.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000781/0001731122-26-000781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226000781/e7667_8-k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-065180","ticker":"ADGM","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2026-05-21T20:31:34+00:00","headline":"Adagio submits PMA to FDA for vCLAS VT ablation system; trial shows 97.4% acute success","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-065180","json":"https://secwatch.observer/filing/0001104659-26-065180.json","markdown":"https://secwatch.observer/filing/0001104659-26-065180.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926065180/0001104659-26-065180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000110465926065180/tm2614299d2_8k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-064863","ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2026-05-21T11:34:37+00:00","headline":"Cognition Therapeutics completes productive FDA meeting for zervimesine in DLB psychosis","event_type":"regulatory","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-064863","json":"https://secwatch.observer/filing/0001104659-26-064863.json","markdown":"https://secwatch.observer/filing/0001104659-26-064863.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926064863/0001104659-26-064863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926064863/tm2615260d1_8k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}